FDA gives the greenlight for Vumerity for MS

US approval has been secured by Biogen and Alkermes for Vulmerity (diroximel fumarate) or treating relapsing forms of multiple sclerosis (MS).

Biogen, which holds the exclusive worldwide license to commercialise Vulmerity, said it intends to make it available in the United States in the near future.

Vumerity is a novel fumarate that offers the efficacy of Tecfidera (dimethyl fumarate) and has been studied for improved patient-reported gastrointestinal tolerability.

The approval was based on a New Drug Application (NDA) which included data from pharmacokinetic bridging studies comparing Vumerity and Tecfidera to establish bioequivalence.

As per the company’s licensing and collaboration agreement, the approval means that Biogen will now make the milestone payment f $150 million to Alkermes.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news